SCHEMBL273692

SCHEMBL273692

O=C(Nc1ccc(Br)cc1C(=O)N/N=C/c1ccc(Cl)c(C(F)(F)F)c1)c1ccno1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 1/20 0.41
RPS6KB1 P23443 1/20 0.41
KMT2A Q03164 6/20 0.39
MEN1 O00255 5/20 0.39
OPRK1 P41145 1/20 0.39
RXFP1 Q9HBX9 2/20 0.39
RXFP2 Q8WXD0 1/20 0.39
POLB P06746 4/20 0.39
LMNA P02545 2/20 0.39
NPC1 O15118 3/20 0.39
RAB9A P51151 2/20 0.39
NPFFR1 Q9GZQ6 2/20 0.38
NPFFR2 Q9Y5X5 2/20 0.38
MAPT P10636 5/20 0.37
ALDH1A1 P00352 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
KDM4E B2RXH2 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
ALOX12 P18054 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL265755 1.00 AURKA (0.41) AURKARPS6KB1KMT2AMEN1OPRK1
SCHEMBL273628 0.86 NPSR1 (0.52) KMT2AMEN1LMNANPC1RAB9A
SCHEMBL268798 0.86 NPSR1 (0.52) KMT2AMEN1LMNANPC1RAB9A
SCHEMBL273687 0.86 GRM4 (0.53) KMT2AMEN1OPRK1POLBLMNA
SCHEMBL267372 0.86 NPC1 (0.48) KMT2AMEN1RXFP1POLBLMNA
SCHEMBL266825 0.86 GRM4 (0.53) KMT2AMEN1OPRK1POLBLMNA
SCHEMBL273927 0.86 NPC1 (0.48) KMT2AMEN1RXFP1POLBLMNA
SCHEMBL267373 0.86 NPC1 (0.48) KMT2AMEN1RXFP1POLBLMNA
SCHEMBL267208 0.83 KMT2A (0.50) KMT2AMEN1POLBNPC1RAB9A
SCHEMBL273362 0.83 KMT2A (0.50) KMT2AMEN1POLBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 AURKA 3228/4885RPS6KB1 1694/4885KMT2A 4603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.